Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate th...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/df0abb92c51246bdb91afa4e4eef1f91 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:df0abb92c51246bdb91afa4e4eef1f91 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:df0abb92c51246bdb91afa4e4eef1f912021-12-04T04:33:59ZOutcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.2213-048910.1016/j.lrr.2021.100284https://doaj.org/article/df0abb92c51246bdb91afa4e4eef1f912021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2213048921000510https://doaj.org/toc/2213-0489In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.Kanta DeviMuhammad Usman ShaikhNatasha Bahadur AliSalman Naseem AdilMaria KhanSalman Muhammad SoomarElsevierarticleDiffuse large B-cell lymphomaNon-hodgkin lymphomaR-DA-EPOCHR-CHOPSurvivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLeukemia Research Reports, Vol 16, Iss , Pp 100284- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Diffuse large B-cell lymphoma Non-hodgkin lymphoma R-DA-EPOCH R-CHOP Survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Diffuse large B-cell lymphoma Non-hodgkin lymphoma R-DA-EPOCH R-CHOP Survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Kanta Devi Muhammad Usman Shaikh Natasha Bahadur Ali Salman Naseem Adil Maria Khan Salman Muhammad Soomar Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience. |
| description |
In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar. |
| format |
article |
| author |
Kanta Devi Muhammad Usman Shaikh Natasha Bahadur Ali Salman Naseem Adil Maria Khan Salman Muhammad Soomar |
| author_facet |
Kanta Devi Muhammad Usman Shaikh Natasha Bahadur Ali Salman Naseem Adil Maria Khan Salman Muhammad Soomar |
| author_sort |
Kanta Devi |
| title |
Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience. |
| title_short |
Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience. |
| title_full |
Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience. |
| title_fullStr |
Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience. |
| title_full_unstemmed |
Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience. |
| title_sort |
outcomes of patients with double/triple expressor diffuse large b-cell lymphoma (dlbcl) treated with r-da-epoch/r-chop: a single-center experience. |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/df0abb92c51246bdb91afa4e4eef1f91 |
| work_keys_str_mv |
AT kantadevi outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience AT muhammadusmanshaikh outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience AT natashabahadurali outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience AT salmannaseemadil outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience AT mariakhan outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience AT salmanmuhammadsoomar outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience |
| _version_ |
1718372999650869248 |